Adamas Pharmaceuticals reported 25.9M in Sales Revenues for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Sales Change
Abbvie ABBV:US $ 14342M 383M
Acadia Pharmaceuticals ACAD:US $ 131.61M 16.39M
Acorda Therapeutics ACOR:US $ 31.46M 0.33M
Adamas Pharmaceuticals ADMS:US 25.9M 3.92M
Aerie Pharmaceuticals AERI:US $ 29.31M 2.13M
Aptinyx Inc APTX:US $ 0 0
Biocryst Pharmaceuticals BCRX:US $ 40.99M 8.96M
Flexion Therapeutics FLXN:US $ 21.33M 6.85M
GlaxoSmithKline GSK:LN 9077M 985M
Glaxosmithkline GSK:US $ 9077M 985M
Gw Pharmaceuticals GWPH:US $ 152.47M 4.24M
Heron Therapeutics HRTX:US $ 23.23M 0.79M
Intra Cellular Therapies ITCI:US $ 22.21M 2.16M
Marinus Pharmaceuticals MRNS:US 10.11M 8.21M
Merk MRK:US $ 13154M 1752M
Neurocrine Biosciences NBIX:US $ 296M 7.1M
Novartis NOVN:VX SF 13367M 73M
Omeros OMER:US $ 30M 1.18M
Prothena PRTA:US 139.17M 79.1M
Revance Therapeutics RVNC:US $ 19.74M 0.94M
Teva Pharmaceutical TEVA:IT 3.89B 23M
Zogenix ZGNX:US $ 22.61M 3.82M